Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Among authors: eriksson jw. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Lundkvist P, et al. Among authors: eriksson jw. Diabetes Obes Metab. 2017 Jan;19(1):49-60. doi: 10.1111/dom.12779. Epub 2016 Sep 26. Diabetes Obes Metab. 2017. PMID: 27550386 Free PMC article. Clinical Trial.
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: eriksson jw. Diabetes Res Clin Pract. 2017 Jan;123:199-208. doi: 10.1016/j.diabres.2016.12.004. Epub 2016 Dec 19. Diabetes Res Clin Pract. 2017. PMID: 28056431 Free article.
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: eriksson jw. Diabetes Obes Metab. 2017 Jun;19(6):831-841. doi: 10.1111/dom.12889. Epub 2017 Mar 16. Diabetes Obes Metab. 2017. PMID: 28116795 Free PMC article.
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Lundkvist P, et al. Among authors: eriksson jw. Diabetes Obes Metab. 2017 Sep;19(9):1276-1288. doi: 10.1111/dom.12954. Epub 2017 May 31. Diabetes Obes Metab. 2017. PMID: 28345814 Free PMC article. Clinical Trial.
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Persson F, et al. Among authors: eriksson jw. Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8. Diabetes Obes Metab. 2018. PMID: 28771923 Free PMC article.
Overweight, hyperglycemia and tobacco use are modifiable risk factors for onset of retinopathy 9 and 17years after the diagnosis of diabetes - A retrospective observational nation-wide cohort study.
Tyrberg M, Nyström L, Arnqvist HJ, Bolinder J, Gudbjörnsdottir S, Landin-Olsson M, Eriksson JW, Svensson MK. Tyrberg M, et al. Among authors: eriksson jw. Diabetes Res Clin Pract. 2017 Nov;133:21-29. doi: 10.1016/j.diabres.2017.08.009. Epub 2017 Aug 24. Diabetes Res Clin Pract. 2017. PMID: 28888147
241 results